Valuation: Transgene

Market Cap 199M 227M 185M 170M 320M 21.93B 325M 2.2B 862M 10.73B 853M 835M 37.07B P/E 2026 *
-5.19x
P/E 2027 * -3.3x
Enterprise Value 130M 148M 121M 111M 209M 14.31B 212M 1.44B 562M 7B 557M 545M 24.18B EV / Sales 2026 *
18x
EV / Sales 2027 * 26.6x
Free-Float
19.4%
Yield 2026 *
-
Yield 2027 * -
1 day-0.68%
1 week-1.76%
Current month+0.28%
1 month-2.68%
3 months-3.58%
6 months-20.81%
Current year-24.27%
1 week 0.72
Extreme 0.725
0.74
1 month 0.72
Extreme 0.722
0.78
Current year 0.72
Extreme 0.722
1.03
1 year 0.72
Extreme 0.722
1.5
3 years 0.53
Extreme 0.53
1.86
5 years 0.53
Extreme 0.53
2.99
10 years 0.53
Extreme 0.53
3.79
Manager TitleAgeSince
Chief Executive Officer 65 2023-05-31
Director of Finance/CFO - 2024-03-26
Chief Tech/Sci/R&D Officer - 2025-04-01
Director TitleAgeSince
Director/Board Member 61 2010-07-26
Director/Board Member 76 2013-06-18
Director/Board Member 88 2006-12-31
Date Insider Type Main position Quantity % Market Cap.
12/2/25
Compagnie Merieux Alliance SAS
BuyCompany 38,492,172 28.9953%
12/2/25
Compagnie Merieux Alliance SAS
BuyCompany 84,745,400 63.8367%
8/2/24
Compagnie Merieux Alliance SAS
BuyCompany 30,898,876 23.3562%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-1.76%-8.67%-60.27% 227M
-0.43%-4.26%+52.09%+85.69% 55.27B
-0.24%+1.04%+55.76%+54.21% 54.15B
-1.82%-2.89%+3.61%+405.88% 23.11B
-0.54%-0.17%-17.60%-15.43% 23.22B
+0.31%-0.92%+35.51%-3.92% 20.33B
+3.16%+0.79%+37.98%-31.36% 17.91B
+0.58%-0.48%+38.67%+551.63% 15.76B
+0.43%-10.61%+175.63%+299.61% 15B
-2.03%-1.03%+23.63%+179.23% 13.82B
Average -0.13%-0.81%+39.66%+146.53% 23.88B
Weighted average by Cap. -0.17%-0.44%+44.15%+132.77%

Financials

2026 *2027 *
Net sales 7.2M 8.22M 6.68M 6.14M 11.57M 793M 11.74M 79.63M 31.17M 388M 30.85M 30.18M 1.34B 7.2M 8.22M 6.68M 6.14M 11.57M 793M 11.74M 79.63M 31.17M 388M 30.85M 30.18M 1.34B
Net income -38.2M -43.6M -35.46M -32.59M -61.41M -4.21B -62.31M -422M -165M -2.06B -164M -160M -7.11B -61.6M -70.3M -57.19M -52.55M -99.02M -6.78B -100M -681M -267M -3.32B -264M -258M -11.47B
Net Debt -69.2M -78.98M -64.24M -59.03M -111M -7.62B -113M -765M -300M -3.73B -296M -290M -12.88B -7.7M -8.79M -7.15M -6.57M -12.38M -848M -12.56M -85.16M -33.33M -415M -32.99M -32.28M -1.43B
Logo Transgene
Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.
Employees
145
Date Price Change Volume
26-07-22 €0.7270 -0.68% 27,190
26-07-21 €0.7320 -0.27% 11,677
26-07-20 €0.7340 -0.41% 44,346
26-07-17 €0.7370 +0.82% 59,288
26-07-16 €0.7310 -1.22% 23,571
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7270EUR
Average target price
1.100EUR
Spread / Average Target
+51.31%

Annual profits - Rate of surprise